ASH 2019 | Safety and activity of CD5 CAR-T for R/R T-ALL and T-NHL
LaQuisa Hill
• 8 Dec 2019
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, discusses the safety and anti-tumor activity of CD5-targeting CAR T-cells in relapsed/refractory (R/R) T-cell malignancies from a phase 1 study (NCT03081910). The results indicated that CD5 CAR T-cells are safe and can induce clinical responses in heavily treated patients with R/R CD5+ T-ALL and T-NHL without inducing complete T-cell aplasia. Importantly, elimination of malignant T-cells may allow previously ineligible patients to proceed to transplant. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
